Abstract
Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.
| Original language | English |
|---|---|
| Pages (from-to) | 4309-4316 |
| Number of pages | 8 |
| Journal | Current Medicinal Chemistry |
| Volume | 23 |
| Issue number | 38 |
| DOIs | |
| Publication status | Published - 01-11-2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Pharmacology
Cite this
}
Current and future drug treatments for glioblastomas. / Oba, Shigeo; Hirose, Yuichi.
In: Current Medicinal Chemistry, Vol. 23, No. 38, 01.11.2016, p. 4309-4316.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Current and future drug treatments for glioblastomas
AU - Oba, Shigeo
AU - Hirose, Yuichi
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.
AB - Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.
UR - http://www.scopus.com/inward/record.url?scp=85006791726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006791726&partnerID=8YFLogxK
U2 - 10.2174/0929867323666161014132907
DO - 10.2174/0929867323666161014132907
M3 - Review article
C2 - 27758718
AN - SCOPUS:85006791726
VL - 23
SP - 4309
EP - 4316
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 38
ER -